
Anastasios Dimou

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4287127/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Predictive value of oncogenic driver subtype, programmed deathâ€1 ligand (PDâ€L1) score, and smoking status on the efficacy of PDâ€1/PDâ€L1 inhibitors in patients with oncogeneâ€driven non–small cell lung cancer. Cancer, 2019, 125, 1038-1049.	2.0	66
2	ROS1 Gene Rearrangements Are Associated With an Elevated Risk of Peridiagnosis Thromboembolic Events. Journal of Thoracic Oncology, 2019, 14, 596-605.	0.5	56
3	Inhibition of the Hedgehog pathway in lung cancer. Lung Cancer, 2019, 133, 56-61.	0.9	13
4	Detection of NRG1 Fusions in Solid Tumors: Rare Gold?. Clinical Cancer Research, 2019, 25, 4865-4867.	3.2	8
5	The Role of GSK3β in T Lymphocytes in the Tumor Microenvironment. Frontiers in Oncology, 2020, 10, 1221.	1.3	7
6	HLA Class I Binding of Mutant EGFR Peptides in NSCLC Is Associated With Improved Survival. Journal of Thoracic Oncology, 2021, 16, 104-112.	0.5	6
7	Real-world characteristics and outcomes of advanced non-small-cell lung cancer patients with <i>EGFR</i> exon 19 deletions or exon 21 mutations. Future Oncology, 2021, 17, 2867-2881.	1.1	5
8	Granulomatosis with polyangiitis in a patient treated with dabrafenib and trametinib for BRAF V600E positive lung adenocarcinoma. BMC Cancer, 2020, 20, 177.	1.1	4
9	Changing paradigm in advanced and metastatic non-small cell lung cancer. Journal of Thoracic Disease, 2020, 12, 6992-7001.	0.6	3
10	Cecal Volvulus as a Rare Complication of Osimertinib Dosed at 160 mg in Patients With EGFR-Mutant Non-small Cell Lung Cancer. Frontiers in Oncology, 2020, 10, 510.	1.3	3
11	The immunologic balance. Melanoma Research, 2021, Publish Ahead of Print, .	0.6	1